Qingdao Saber Technology Pharmaceutical: difference between revisions
Diff·revision 22 → 23·10:50, 17 Sep 2025
Difference between revision 22 and revision 23 of Qingdao Saber Technology Pharmaceutical. 5 lines changed; the page grew by 781 bytes.
| Revision 22 — 23:19, 9 Sep 2025 LabRangeLindy (talk) update infobox 6,629 bytes ±0 | Revision 23 — 10:50, 17 Sep 2025 ForestPlotFinn (talk) move table to the section it supports 7,410 bytes +781 | ||
|---|---|---|---|
| 47 | | Raw materials and oils | Bulk | Certificate, limited detail | | 47 | | Raw materials and oils | Bulk | Certificate, limited detail | |
| 48 | 48 | ||
| + | 49 | The catalogue follows the sector pattern. Documentation is better on the peptide lines than the bulk lines, as on most of these articles.{{r|reports}} | |
| + | 50 | ||
| 49 | == Independent testing record == | 51 | == Independent testing record == |
| 50 | Submitted reports on QST material to July 2026 are fewer than for the larger entries, reflecting a smaller reported customer base rather than a quality finding.{{r|reports}} Reported [[Area percent purity|area percent]] figures have been high in most cases. | 52 | Submitted reports on QST material to July 2026 are fewer than for the larger entries, reflecting a smaller reported customer base rather than a quality finding.{{r|reports}} Reported [[Area percent purity|area percent]] figures have been high in most cases. |
| 51 | 53 | ||
| + | 54 | One report in the set concerned a vial whose contents did not reconstitute to a clear solution. Visible particulate or incomplete dissolution is an appearance failure that a purity figure obtained on the dissolved fraction will not reveal, since the assay measures what went into the injector.{{r|usp1503}} A single report establishes nothing about the organisation and is recorded because the failure mode is one readers should know to look for. | |
| + | 55 | ||
| 52 | == References == | 56 | == References == |
| 53 | {{reflist}} | 57 | {{reflist}} |
| ⋮ | ⋮ | ||
| 56 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 60 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 57 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 61 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 62 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 58 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 63 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 59 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 64 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |